Oligo Medic strives to provide innovations that enable less invasive surgical treatments, always simplifying the surgeon’s workflow
Obtained license from TGA for JointRep® in Australia.
Obtained license from Health Canada for JointRep®.
Preliminary steps taken toward procedures with FDA for market approval in the US.
Gaining market penetration in Europe, ANZ regions, Middle East, South East Asia, and Latin America
Very favorable results on clinical trial published in Journal of Clinical Orthopedics and Trauma.
Other clinical trials on different indications are planned and will be disclosed when protocols are defined.
Initiated European controlled clinical trial: 69 patients and comparing microfracture to microfracture & JointRep®.
Initial experimentation with JointRep® and microfracture. Results are highly favorable with fast pain relief, accelerated recovery time, and nice cartilage regrowth.
Structured OligoMedic for distribution partnership and initiated case studies and post market evaluation.
2012Manufacturing, packaging, and shipping processes defined. Obtained CE mark in October.
Follow up case series on Health Canada SAP.
Creation of Oligo Medic Inc. Development of technology platform. Bench testing and pre-clinical characterization. Initiated Health Canada Special Access Program ("SAP"). Successful first-in-man JointRep® operation.